Regeneron says Phase 2 COURAGE trial shows trevogrumab preserves lean mass during semaglutide weight loss

• Regeneron reported new Phase 2 COURAGE results showing trevogrumab helped preserve muscle during semaglutide-driven weight loss in obesity.
• Findings were already presented at the EASD Annual Meeting, with the study in press at The Lancet.
• MRI and body-composition assessments indicated patients kept substantially more muscle versus semaglutide alone, without boosting overall weight-loss results.
• Subgroup analysis suggested greater benefit in participants starting with low lean mass, a group more exposed to muscle loss on semaglutide alone.
• Regeneron plans another Phase 2 trial pairing trevogrumab with GLP-1-based therapies in older adults with obesity and reduced muscle mass or strength.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011130PRIMZONEFULLFEED9837857) on October 01, 2026, and is solely responsible for the information contained therein.